FierceBiotech 12 mars 2026 Pfizer Ignite, designed to accelerate promising biotech therapies, fizzles out
Agilent 9 mars 2026 Hims & Hers shares soar premarket; Pfizer, Agilent Technologies slip - Investing.com
BioPharma Dive 6 mars 2026 Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs
Endpoints News 6 mars 2026 Pfizer gets obesity drug approval in China shortly after buying local rights
FierceBiotech 4 mars 2026 Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations
FierceBiotech 25 févr. 2026 After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate
Endpoints News 24 févr. 2026 Pfizer buys China rights to Sciwind’s approved GLP-1 drug in metabolic push
Endpoints News 7 févr. 2026 The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more
FierceBiotech 6 févr. 2026 Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study
BioPharma Dive 4 févr. 2026 Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan
FierceBiotech 4 févr. 2026 Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1
FierceBiotech 3 févr. 2026 Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges